- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Renal cell carcinoma (RCC)
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 1.2MB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 673KB)
Pembrolizumab – November 2024
Pembrolizumab; Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
Last updated
30 May 2025